A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors
Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Archival tumor sampl...
Saved in:
| Published in | PloS one Vol. 18; no. 8; p. e0290681 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
San Francisco
Public Library of Science
30.08.2023
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0290681 |
Cover
| Abstract | Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0-100%. The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score [less than or equal to] 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51-1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48-0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. |
|---|---|
| AbstractList | Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0-100%. The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score [less than or equal to] 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51-1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48-0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Patients and methods Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0-100%. Results The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score [less than or equal to] 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51-1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48-0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. Conclusion The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Patients and methods Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0–100%. Results The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51–1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48–0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. Conclusion The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively.PURPOSEDovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively.Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0-100%.PATIENTS AND METHODSArchival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0-100%.The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51-1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48-0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend.RESULTSThe DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51-1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48-0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend.The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients.CONCLUSIONThe DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. Patients and methods Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the in vitro sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0–100%. Results The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score >50%) or resistant (n = 86, DRP score ≤ 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51–1.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48–0.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend. Conclusion The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients. |
| Audience | Academic |
| Author | Mekonnen, Hana Martin, Victoria Shah, Preeti Hansen, Anker Foegh, Marie Petersen, Steen Jia, Lin Frykman, Gregory Pili, Roberto Knudsen, Steen |
| AuthorAffiliation | 5 Jacobs School of Medicine, Buffalo, NY, United States of America University of Granada: Universidad de Granada, SPAIN 2 Allarity Therapeutics, Boston, MA, United States of America 3 Amarex Clinical Research, Germantown, MD, United States of America 4 Bethesda, MD, United States of America 1 Allarity Therapeutics, Hørsholm, Denmark |
| AuthorAffiliation_xml | – name: 1 Allarity Therapeutics, Hørsholm, Denmark – name: 3 Amarex Clinical Research, Germantown, MD, United States of America – name: 5 Jacobs School of Medicine, Buffalo, NY, United States of America – name: 2 Allarity Therapeutics, Boston, MA, United States of America – name: 4 Bethesda, MD, United States of America – name: University of Granada: Universidad de Granada, SPAIN |
| Author_xml | – sequence: 1 givenname: Steen orcidid: 0000-0001-9503-2504 surname: Knudsen fullname: Knudsen, Steen – sequence: 2 givenname: Anker surname: Hansen fullname: Hansen, Anker – sequence: 3 givenname: Marie surname: Foegh fullname: Foegh, Marie – sequence: 4 givenname: Steen surname: Petersen fullname: Petersen, Steen – sequence: 5 givenname: Hana surname: Mekonnen fullname: Mekonnen, Hana – sequence: 6 givenname: Lin surname: Jia fullname: Jia, Lin – sequence: 7 givenname: Preeti surname: Shah fullname: Shah, Preeti – sequence: 8 givenname: Victoria surname: Martin fullname: Martin, Victoria – sequence: 9 givenname: Gregory surname: Frykman fullname: Frykman, Gregory – sequence: 10 givenname: Roberto surname: Pili fullname: Pili, Roberto |
| BookMark | eNqNkmtrFDEUhgepYLv6DwQDguiHXTPXZPwiS_GyUCzUy9dwJsnsps4kY5JZ7d_xl3qmu0q3FCzDXDjznPdc3pwkR9ZZnSRPU7pIc5a-vnSjt9AtBgwvaFbTiqcPkuO0zrN5ldH86Mb3o-QkhEtKy5xX1XHye0ms2-qOKD-uSRi0NK2RpL_4tCSNcT3479qTwWtlZHSetHgH3WkZjbPEtWSAaLSNgXgdsL4ydk2iI8ptTTTWNCR6DbFHZKJBbcFKrZDGhonUHT7AS2OxFAGriIsbLBhcZxSJY-98eJw8bKEL-sn-PUu-vn_35fTj_Oz8w-p0eTaXFaNx3mRVzvOsoAw4gE5l3qayVYxSpmqmSsapzphq8lQWTKWMsZqVChrdVLxSaZ7Pkmc73aFzQex3GkTGS16XlBUFEqsdoRxcisEbXM-VcGDEdcD5tQAfjey0qMu6kW2RsYJXheYNpDXnHCholKpTjlrlTmu0A1z9hK77J5hSMdn6twUx2Sr2tmLe232XY9NrJXGxHrqDZg7_WLMRa7dF1aLiNGeo8HKv4N2PUYcoehMmJ8BqN14PXFc0LxGeJc9voXevZU-tASc3tnVYWE6iYsmqjOPorEZqcQeFl9K9kThiazB-kPDqIAGZqH_FNYwhiNXni_uz598O2Rc32I2GLm7wvI3TiQ6H4JsdKL0LwetWSBNhwrBz0_3Pp-JW8r3s_QOEKzj1 |
| CitedBy_id | crossref_primary_10_3390_medicina60101626 |
| Cites_doi | 10.1684/ecn.2009.0175 10.1002/hep.28600 10.1158/0008-5472.CAN-04-1443 10.1371/journal.pone.0087415 10.1371/journal.pone.0115538 10.1016/j.gene.2017.10.071 10.18632/oncotarget.8203 10.1200/jco.2010.28.15_suppl.4621 10.1002/ijc.32256 10.1038/s41416-020-0916-5 10.1016/S1470-2045(14)70030-0 10.1186/s13058-017-0807-8 10.1158/1078-0432.CCR-13-0190 10.1158/1078-0432.CCR-04-2129 10.1371/journal.pone.0155123 10.1038/bjc.2017.290 10.1158/1535-7163.MCT-17-1299 10.1016/j.cell.2017.01.017 10.3390/ijms21134691 10.1016/S1470-2045(15)70159-2 10.1371/journal.pone.0194609 10.1634/theoncologist.2011-S2-14 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 Public Library of Science 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: © 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 2023 Knudsen et al 2023 Knudsen et al 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2023 Public Library of Science – notice: 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: © 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: 2023 Knudsen et al 2023 Knudsen et al – notice: 2023 Knudsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1371/journal.pone.0290681 |
| DatabaseName | CrossRef Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) SciTech Premium Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection (ProQuest) ProQuest Central Essentials Local Electronic Collection Information Biological Science Database ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Dovitinib biomarker |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2858950744 oai_doaj_org_article_959bcf4274864e8ba19888a0ae507918 10.1371/journal.pone.0290681 PMC10468037 A762819879 10_1371_journal_pone_0290681 |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM ADRAZ ADTOC IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c670t-b263832407a8aae1c3f1cfd7007d97d5780e27db31c47d1777975dabeb686d133 |
| IEDL.DBID | UNPAY |
| ISSN | 1932-6203 |
| IngestDate | Thu Nov 28 02:59:24 EST 2024 Fri Oct 03 12:52:36 EDT 2025 Sun Oct 26 03:42:52 EDT 2025 Tue Sep 30 17:12:52 EDT 2025 Fri Sep 05 09:28:46 EDT 2025 Tue Oct 07 07:48:44 EDT 2025 Mon Oct 20 22:35:38 EDT 2025 Mon Oct 20 17:17:42 EDT 2025 Thu Oct 16 16:15:42 EDT 2025 Thu Oct 16 16:17:11 EDT 2025 Thu May 22 21:21:18 EDT 2025 Wed Oct 01 03:14:10 EDT 2025 Thu Apr 24 23:10:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. cc-by Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c670t-b263832407a8aae1c3f1cfd7007d97d5780e27db31c47d1777975dabeb686d133 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following financial disclosure and competing interests: This study was sponsored by Allarity Therapeutics (www.allarity.com). SK, AH and MF are employees of Allarity and hold stock or stock options. HM, LJ, PS, VM are employees of a CRO engaged by Allarity. SP, GF and RP are consultants to Allarity. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| ORCID | 0000-0001-9503-2504 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290681&type=printable |
| PQID | 2858950744 |
| PQPubID | 1436336 |
| PageCount | e0290681 |
| ParticipantIDs | plos_journals_2858950744 doaj_primary_oai_doaj_org_article_959bcf4274864e8ba19888a0ae507918 unpaywall_primary_10_1371_journal_pone_0290681 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10468037 proquest_miscellaneous_2859603580 proquest_journals_2858950744 gale_infotracmisc_A762819879 gale_infotracacademiconefile_A762819879 gale_incontextgauss_ISR_A762819879 gale_incontextgauss_IOV_A762819879 gale_healthsolutions_A762819879 crossref_citationtrail_10_1371_journal_pone_0290681 crossref_primary_10_1371_journal_pone_0290681 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-30 |
| PublicationDateYYYYMMDD | 2023-08-30 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-30 day: 30 |
| PublicationDecade | 2020 |
| PublicationPlace | San Francisco |
| PublicationPlace_xml | – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationYear | 2023 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | P Alessi (pone.0290681.ref003) 2009; 20 S Knudsen (pone.0290681.ref009) 2014; 9 GE Konecny (pone.0290681.ref018) 2015; 16 P Sharma (pone.0290681.ref008) 2017; 168 R Plummer (pone.0290681.ref015) 2020; 123 H Joensuu (pone.0290681.ref019) 2017; 117 ASK Buhl (pone.0290681.ref014) 2018 IK Buhl (pone.0290681.ref011) 2016; 11 IK Buhl (pone.0290681.ref013) 2018; 13 AL Cheng (pone.0290681.ref017) 2016; 64 RJ Motzer (pone.0290681.ref016) 2014; 15 F André (pone.0290681.ref020) 2013; 19 I Tsimafeyeu (pone.0290681.ref004) 2010; 28 A Musolino (pone.0290681.ref021) 2017; 19 MR Akl (pone.0290681.ref005) 2016; 7 SM Wilhelm (pone.0290681.ref023) 2004; 64 TE Hutson (pone.0290681.ref001) 2011; 162 D Lavacchi (pone.0290681.ref006) 2020; 21 P Makhov (pone.0290681.ref007) 2018; 17 S Knudsen (pone.0290681.ref010) 2015; 10 AJ Vangsted (pone.0290681.ref012) 2018; 644 S Lee (pone.0290681.ref022) 2005; 11 M Elgendy (pone.0290681.ref002) 2019; 145 |
| References_xml | – volume: 20 start-page: 225 issue: 4 year: 2009 ident: pone.0290681.ref003 article-title: Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist publication-title: European cytokine network doi: 10.1684/ecn.2009.0175 – volume: 64 start-page: 774 year: 2016 ident: pone.0290681.ref017 article-title: Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma publication-title: Hepatology doi: 10.1002/hep.28600 – volume: 64 start-page: 7099 issue: 19 year: 2004 ident: pone.0290681.ref023 article-title: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1443 – volume: 9 start-page: e87415 issue: 2 year: 2014 ident: pone.0290681.ref009 article-title: Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients publication-title: PLoS One doi: 10.1371/journal.pone.0087415 – volume: 10 start-page: e0115538 issue: 2 year: 2015 ident: pone.0290681.ref010 article-title: Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL publication-title: PLoS One doi: 10.1371/journal.pone.0115538 – volume: 644 start-page: 80 year: 2018 ident: pone.0290681.ref012 article-title: Drug response prediction in high-risk multiple myeloma publication-title: Gene doi: 10.1016/j.gene.2017.10.071 – volume: 7 start-page: 44735 issue: 28 year: 2016 ident: pone.0290681.ref005 article-title: Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies publication-title: Oncotarget doi: 10.18632/oncotarget.8203 – volume: 28 start-page: 4621 issue: 15 year: 2010 ident: pone.0290681.ref004 article-title: Fibroblast growth factor pathway in renal cell carcinoma publication-title: Journal of Clinical Oncology doi: 10.1200/jco.2010.28.15_suppl.4621 – volume: 145 start-page: 1991 issue: 7 year: 2019 ident: pone.0290681.ref002 article-title: Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer publication-title: International journal of cancer doi: 10.1002/ijc.32256 – volume: 123 start-page: 525 issue: 4 year: 2020 ident: pone.0290681.ref015 article-title: First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor publication-title: Br J Cancer doi: 10.1038/s41416-020-0916-5 – volume: 15 start-page: 286 year: 2014 ident: pone.0290681.ref016 article-title: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70030-0 – volume: 19 start-page: 18 year: 2017 ident: pone.0290681.ref021 article-title: Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy publication-title: Breast Cancer Research doi: 10.1186/s13058-017-0807-8 – volume: 19 start-page: 3693 issue: 13 year: 2013 ident: pone.0290681.ref020 article-title: Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0190 – volume: 11 start-page: 3633 issue: 10 year: 2005 ident: pone.0290681.ref022 article-title: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2129 – volume: 11 start-page: e0155123 issue: 5 year: 2016 ident: pone.0290681.ref011 article-title: Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data publication-title: PLoS One doi: 10.1371/journal.pone.0155123 – volume: 117 start-page: 1278 year: 2017 ident: pone.0290681.ref019 article-title: Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib publication-title: British Journal of Cancer doi: 10.1038/bjc.2017.290 – volume: 17 start-page: 1355 issue: 7 year: 2018 ident: pone.0290681.ref007 article-title: Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies publication-title: Molecular cancer therapeutics doi: 10.1158/1535-7163.MCT-17-1299 – volume: 168 start-page: 707 issue: 4 year: 2017 ident: pone.0290681.ref008 article-title: Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 21 start-page: 4691 issue: 13 year: 2020 ident: pone.0290681.ref006 article-title: Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective publication-title: International journal of molecular sciences doi: 10.3390/ijms21134691 – volume: 16 start-page: 686 year: 2015 ident: pone.0290681.ref018 article-title: Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70159-2 – volume: 13 start-page: e0194609 issue: 3 year: 2018 ident: pone.0290681.ref013 article-title: Molecular prediction of adjuvant cisplatin efficacy in Non- Small Cell Lung Cancer (NSCLC)—Validation in two independent cohorts publication-title: PLoS ONE doi: 10.1371/journal.pone.0194609 – volume: 162 start-page: 14 issue: Suppl 2 year: 2011 ident: pone.0290681.ref001 article-title: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence publication-title: The oncologist doi: 10.1634/theoncologist.2011-S2-14 – year: 2018 ident: pone.0290681.ref014 article-title: Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study publication-title: Breast Cancer Res Treat |
| SSID | ssj0053866 |
| Score | 2.4362826 |
| Snippet | Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP)... Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP)... Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP)... |
| SourceID | plos doaj unpaywall pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | e0290681 |
| SubjectTerms | 1-Phosphatidylinositol 3-kinase AKT protein Algorithms Biological markers Biology and Life Sciences Biomarkers Biopsy Breast cancer c-Kit protein Cancer Cancer therapies Carcinoma, Renal cell Care and treatment Chemotherapy Clinical outcomes Clinical trials Disease Drug therapy Endometrial cancer Ethics Fibroblast growth factor receptor 1 Health aspects Informed consent Inhibitor drugs Kidney cancer Kinases Liver cancer Medicine and Health Sciences Messenger RNA Metastasis mRNA Oncology, Experimental Patients Platelet-derived growth factor Prognosis Protein-tyrosine kinase receptors Renal cell carcinoma Solid tumors Statistical analysis Survival Targeted cancer therapy TOR protein Tumors Tyrosine Vascular endothelial growth factor |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQL3BBlIcaKGAQEnDINg8nto8LoipIFKlQ1FvkOHZZaZus8iji7_BLmXG8UYOQ2gPXeLJJ5uWZnZnPhLwSKlEpYzKUNhchS5UGk7KgyxYcsuRa5a6i-_k4Pzpln86ysytHfWFP2AgPPDLuQGay1JZB8iRyZkSpIEsWQkXKQCQjYzfmGwm5TaZGHwxWnOd-UC7l8YGXy2LT1GYRIcK5iGcbkcPrn7zyzmbddLOQ8--GydtDvVG_fqr1-spudHiP3PVhJF2Or79Lbpn6Ptn1htrRNx5N-u0D8ntJ6-bSrGnVDucUByuxOYhenBwvKc7eY3tOSzctFmwg_6YQxNLOHY4DEqONpR55taOta6fFvY72Da2ay1W_qlclnXrVkXrbUwDU-IJYF6Aazyuq4VFU1RV1I18UVH5V0X64aNruITk9_PDt_VHoD2YIdc6jPiwTsFpE8uNKKGVindpY24pDvAHyrcAJRCbhVZnGmvEq5pxLnlWqNGUu8gqy4kdkpwZR7BGKCROTUaZMrlkcW1ElFvFnSpulMjI2IOlWSoX2qOV4eMa6cKU4DtnLyPECZVt42QYknO7ajKgd19C_QwWYaBFz210ATSy8JhbXaWJAnqP6FOMA6-Q5iiXsNwL_25EBeekoEHejxsaeczV0XfHxy_cbEH09mRG99kS2AXZo5Ycp4JsQz2tGuT-jBO-hZ8t7qOxbrnRFIjIh4YMYgzu3BvDv5RfTMv4oNuvVphkcDeTFWF8PiJgZzozB85V69cOBm2PPgYhSHpDFZGM3kuHj_yHDJ-ROAlGsKxpE-2SnbwfzFKLOvnzmHMwfePyDeA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbK9gAXRHmogQIGIQGHtHnbOSC0Ra0KEgtaKOotcmxnu9I2WfIo4u_wS5nxOoEgBL3Gk03W8_BMZuYbQp5xEYgwilI3LRLuRqGQoFIFyHIBBjllUiQmo_t-lpycRu_O4rMtMut7YbCssreJxlCrSuI38oOAxzwF5yWKXq-_ujg1CrOr_QgNYUcrqFcGYuwa2Q4QGWtCtg-PZh_nvW0G7U4S20AXMv_A8mt_XZV630Pkc-6PDiiD4z9Y68l6VTUjV_TPQsrrXbkW37-J1eq3U-r4Frlp3Us63cjDDtnS5W2yYxW4oS8syvTLO-THlJbVpV5RVXcLig2XWDREL-azKcWefCzbqem6xkQOxOUUnFvamKE5wElaFdQisja0NmW2eAbStqKquly2y3KZ06GGHan7WgOgxhfEfAGVOMeohEdRUSpqWsEoqMJS0ba7qOrmLjk9Pvr85sS1AxtcmTCvdfMAtBkR_pjgQmhfhoUvC8XADwG-KzAOng6YykNfRkz5jLGUxUrkOk94oiBavkcmJbBil1AMpKLUi4VOZOT7BVdBgbg0eRGHqacLh4Q9lzJp0cxxqMYqMyk6BlHNZscz5G1meesQd7hrvUHz-A_9IQrAQItY3OZCVS8yq9pZGqe5LCII73kSaZ4LP-WcC09oENfU5w55jOKTbRpbB4uSTeEc4vjNJ3XIU0OBeBwlFvwsRNc02dsPX65A9Gk-InpuiYoKtkMK22QB_wlxvkaUeyNKsCpytLyLwt7vSpP90j-4s1eAvy8_GZbxR7GIr9RVZ2ggXsa8u0P4SHFGGzxeKZfnBvQcaxG4FzKH7A86diUe3v_36z4gNwLwW02awNsjk7bu9EPwM9v8kTUePwEPCYJh priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaq5QAXRHmogQIGIQGHrPJwYvuA0IKoClKLVFjUW-Q4ybJSmix5FPp3-KXMeJ2IoKL2uh5nN_OwZ3ZmviHkhVCBChmTrixi4bJQaTCpAnS5gANZcq1ik9E9Oo4Pl-zTaXS6Q4aZrZaB7aWhHc6TWjbl_NePi7dg8G_M1AbuD5vmm7rK5x7il2Mv9g24qyQOczhiY14BrNtkL9FrcePAC20z3f-eMrmsDKb_eHLPNmXdTtzSf4sqb_bVRl38VGX51411cIfctq4mXWx1Y5fs5NVdsmuNuaWvLOL063vk94JW9Xle0qzpVxSbL7GAiJ6dHC8o9udjCU9DNw0mdSBGp-Do0tYM0AGp0rqgFp21pY0pucX7kHY1zerzdbeu1ikd69mReqg7AGr8gZg7oBpnGlXwVVRVGTVtYRTMYp3Rrj-rm_Y-WR58-Pr-0LXDG1wdc69z0wAsG9H-uBJK5b4OC18XGQefBHQgg4PCywOepaGvGc98zrnkUabSPI1FnEHk_IDMKhDFHqEYVDHpRSqPNfP9QmRBgRg1aRGF0ssLh4SDlBJtkc1xwEaZmHQdhwhny_EEZZtY2TrEHXdttsgeV9C_QwUYaRGX23xQN6vEmnkiI5nqgkGoL2KWi1T5UgihPJWD3y194ZCnqD7Jtsl1PF2SBdxJAv__kQ55bigQm6PC4p-V6ts2-fj52zWIvpxMiF5aoqIGdmhlGy7gnRDza0K5P6GEE0ZPlvdQ2QeutEkgIiHhhRiDnYMBXL78bFzGh2JBX5XXvaGB2Blz8A4RE8OZMHi6Uq2_GwB0rEsQXsgdMh9t7FoyfHgl-x-RWwG4sSZr4O2TWdf0-WNwO7v0iTlJ_gDDL4Sg priority: 102 providerName: Scholars Portal |
| Title | A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors |
| URI | https://www.proquest.com/docview/2858950744 https://www.proquest.com/docview/2859603580 https://pubmed.ncbi.nlm.nih.gov/PMC10468037 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290681&type=printable https://doaj.org/article/959bcf4274864e8ba19888a0ae507918 http://dx.doi.org/10.1371/journal.pone.0290681 |
| UnpaywallVersion | publishedVersion |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: HH5 dateStart: 20060101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20060101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KQ8 dateStart: 20061001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: ABDBF dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVEBS databaseName: EBSCOhost Food Science Source customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: A8Z dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/login.aspx?authtype=ip,uid&profile=ehost&defaultdb=fsr providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DIK dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: GX1 dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8FG dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1932-6203 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M48 dateStart: 20061201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELba3QNcgPJQF8piEOJxyDYPJ3aO26pLQepSFYraA4qcV1mxTVZ5FMGBH8MvZcZxIlKBKAcu0Wo9duLxeDz2zHwm5KmQtnQY8w0_9YTBHBnBlEpBllNQyD6PpKc8ugdzb_-YvTlxT9bIxzYXRnMQ9ojLvFSefPyRZ8m25uQ24hU13tOJ5XCrrTFZAdHERPRyYT1TiEN4MlZhAtI6GXoumOoDMjyeH05PG0-zbXi26eh0uj-11FuuFKp_p7sH-GU9w_RyWOW1OlvJr1_kcvnLmjW7Sb63vW1CVT5P6iqcRN8uAUH-N3bcIje0tUunTSsbZC3JbpMNrU9K-kKDXr-8Q35MaZZfJEsaF_UZxfxPjGGi50fzKUWIAIwiKuiqQL9SlRcUbG1aqjt8QLBonlINEFvSQkX94pJMq5zG-cWiWmSLkHYh9Ujdhj4ANX4gui9ohNcqZfAqKrOYqsw0CjNzEdOqPs-L8i45nu2939039P0RRuRxszJCG5QLAg5yKaRMrMhJrSiNOZhFIIYx6CozsXkcOlbEeGxxzn3uxjJMQk94MWze75FBBmzcJBT3dcw3XZl4EbOsVMR2ijA5Yeo6vpmkI-K0YhJEGlwd7_hYBspjyGGT1XA8wHEJ9LiMiNHVWjXgIn-h30EJ7GgRGlz9AYIRaIEIfNcPo5TZnAmPJSKUli-EkKZMwPT3LTEij1B-gybPtlNwwRSWRYFHUP6IPFEUCA-SYfzRmazLMnj99sMViN4d9Yiea6I0B3ZEUud8QJ9QbnuUWz1KUHJRr3gTBb_lShnYwhU-dIgxqNnOwN8XP-6KsVGMKcySvFY0oBMwDGBERG_m9hjcL8kWnxQGO4ZGCNPhIzLpJvmVxvD-v1Z4QK7bYFgrP4a5RQZVUScPwRCuwjFZ5yccnmLXwufs1ZgMd_bmh0djdbQEzwMmxlrp_QTrdMGK |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V4VAuiPJQA4UuCAQc3Pqx9q4PCIVHldA2SKVFubnr9TpESu1gO636d_gB_EZmNrbBCEEvvWbHibMz883OzouQZ0K60mMstMI0EBbzpAKVSkGWUwDkkCsZmIju4TgYnrCPE3-yRn40tTCYVtlgogHqJFd4R77rCl-EcHhh7M3im4VTozC62ozQWInFvr68AJetfD16D_x97rp7H47fDa16qoClAm5XVuyCyGEbOi6FlNpRXuqoNOFgLOHlEpBgW7s8iT1HMZ44nPOQ-4mMdRyIIHHwAhQg_wbzAEtAf_ikdfAAO4KgLs_zuLNbS8POIs_0jo191YXTMX9mSkBrC3qLeV52Drp_pmmuL7OFvLyQ8_lvNnDvNrlVH17pYCVtG2RNZ3fIRg0PJX1Z97B-dZd8H9AsP9dzmhTLKcVyTkxJomdH4wHFin9MCiroosAwEXj9FI7OtDQjeUBOaJ7Sut9rSQuTxIsWllY5TfLzWTXLZjFtM-SRuslkAGp8QYxGUIVTkjL4KSqzhJpCMwqKNktotTzLi_IeObkWxt0nvQxYsUkoumkstH2pA8UcJxWJm2LXmzj1vdDWaZ94DZciVfdKx5Ed88gEADn4TKsdj5C3Uc3bPrHapxarXiH_oX-LAtDSYqdv80FeTKMaOKLQD2OVMpczETAtYumEQghpSw3KEDqiT7ZRfKJV2WyLV9EArJzAG6WwT54aCuz2kWE60VQuyzIaffpyBaLPRx2iFzVRmsN2KFmXcMB_wi5iHcqtDiVgluosb6KwN7tSRr-0G55sFODvy0_aZfxSTBHMdL40NOCNY1S_T0RHcTob3F3JZl9NS3XMdBC2x_tkp9WxK_Hwwb9fd5usD48PD6KD0Xj_IbnpwgnZBCTsLdKriqV-BCfaKn5sYISS0-vGrZ_Z6Lgg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXRHmoC4UaBAIO2ea1sX1AaKFULYWCCkW9Bcexy0rbZEmyrfp3-Bn8Oma8TiAIQS-9rie7Wc_MN2PPi5BHXIYyimPhCZNwL46kApUyIMsGAFkwJRMb0X23l2wfxG8OR4dL5EdbC4NplS0mWqDOS4V35BshH3EBzkscbxiXFvFhc-vF7JuHE6Qw0tqO01iIyK4-O4XjW_18ZxN4_TgMt15_erXtuQkDnkqY33hZCOKHLemY5FLqQEUmUCZnYDjhRXOQZl-HLM-iQMUsDxhjgo1ymeks4Uke4GUowP8lFkUC0wnZYXfYAxxJEleqF7Fgw0nGcFYWeuhjj3Ue9EyhnRjQ2YXl2bSse07vnymbV-bFTJ6dyun0N3u4dZ1cc44sHS8kb4Us6eIGWXFQUdOnrp_1s5vk-5gW5Yme0ryaH1Es7cT0JHq8vzemWP2PCUIVnVUYMmrKioIbTWs7ngdkhpaGut6vNa1sQi9aW9qUNC9PJs2kmGS0y5ZH6jarAajxBTEyQRVOTCrgp6gscmqLzigo3SSnzfy4rOpb5OBCGHebLBfAilVC8cgWC38kdaLiIDA8Dw12wMnMKBK-NgMStVxKleubjuM7pqkNBjI4Py12PEXepo63A-J1T80WfUP-Q_8SBaCjxa7f9oOyOkodiKRiJDJl4pDFPIk1z2QgOOfSlxoUQwR8QNZRfNJFCW2HXekYLB7H2yUxIA8tBXb-KFCHjuS8rtOd95_PQfRxv0f0xBGZErZDSVfOAf8JO4r1KNd6lIBfqre8isLe7kqd_tJ0eLJVgL8vP-iW8UsxXbDQ5dzSwMkcI_wDwnuK09vg_kox-Wrbq2PWA_cjNiDDTsfOxcM7_37ddXIZECt9u7O3e5dcDcFZtrEJf40sN9Vc3wPntsnuWxSh5MtFw9ZPoLm8Yw |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXoDzUhQIGIR6HpHnbPi6IqiCxoMKicqgix0nKim2yyqMIDvwYfikzjhORCkQ5cFvFn7PxZDweZ2Y-E_KQS0_6QSAskUfcCnypYErloMs5GGTBlIx0RPf1PNpfBK8Ow8MNctTXwhgJwh5xVdY6ko8_yiLbNZLcRb6iLnpquz5z-x72GkC2g-zl3H2kGYfwy1iDBUgXyGYUgqs-IZuL-dvZxy7S7FmR5_imnO5PdxotV5rVf7DdE3yykWN6Nq3yYlus5dcvcrX6Zc3au0K-96PtUlU-222T2OrbGSLI_yaOq-Sy8XbprLvLFtnIimtky9iTmj4xpNdPr5MfM1qUp9mKplV7TLH-E3OY6MnBfEaRIgCziCq6rjCu1JQVBV-b1voMH1AsWubUEMTWtNJZv7gk06akaXm6bJbFMqFDSj2i-9QHQOMDYviCKjxWqYC_orJIqa5MozAzlylt2pOyqm-Qxd6L98_3LXN-hKUi5jRW4oFxQcJBJrmUmav83FV5ysAtAjVMwVY5mcfSxHdVwFKXMSZYmMokSyIepbB5v0kmBYhxm1Dc1wXCCWUWqcB1c556OdLkJHnoCyfLp8Tv1SRWhlwdz_hYxTpiyGCT1Uk8xvcSm_cyJdbQa92Ri_wF_ww1cMAiNbi-AIoRG4WIRSgSlQceC3gUZDyRruCcS0dm4PoLl0_JPdTfuKuzHQxcPINlkeMnKDElDzQC6UEKzD86lm1dxy_ffDgH6N3BCPTYgPISxKGkqfmAMaHejpA7IyQYOTVq3kbF76VSxx4PuYABBQH07Gfg75vvD814U8wpLLKy1RiwCZgGMCV8NHNHAh63FMtPmoMdUyO447MpsYdJfq53eOtfO9wmlzxwrHUcw9khk6ZqszvgCDfJXWPOfgK2jruH |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+drug+specific+mRNA+biomarker+predictor+for+selection+of+patients+responding+to+dovitinib+treatment+of+advanced+renal+cell+carcinoma+and+other+solid+tumors&rft.jtitle=PloS+one&rft.au=Mekonnen%2C+Hana&rft.au=Petersen%2C+Steen&rft.au=Frykman%2C+Gregory&rft.au=Jia%2C+Lin&rft.date=2023-08-30&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=18&rft.issue=8&rft.spage=e0290681&rft_id=info:doi/10.1371%2Fjournal.pone.0290681&rft.externalDBID=n%2Fa&rft.externalDocID=A762819879 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |